You are here: Industry Insights > Brexit

News List

Industry welcomes progress on Brexit pharmatimes
March 27, 2018
Pharmaceutical industry representatives have applauded the decision to progress Brexit negotiations to the next phase, with the UK and EU having agreed the terms of the transition period.
GSK welcomes Brexit transition deal, but wants more ‘precision’ on final relationship pharmaphorum
March 21, 2018
The chief executive of GlaxoSmithKline has welcomed the breakthrough in talks between the UK and EU27 countries on a transition or ‘implementation’ period.
GSK expects Brexit admin to cost £70m pharmaphorum
March 19, 2018
GlaxoSmithKline expects Brexit to cost it £70m over the next three years, with ongoing costs of £50m, according to estimates in its annual report.
Brexit may disrupt medicines supply, warns British alliance pharmaceutical-technology
January 31, 2018
The alliance cited an example that around 120,000 prostate cancer patients across Europe might be affected if Brexit negotiations fail to secure a future collaboration on regulation and trade of medicines and medical devices.
Brexit Alliance calls for Brexit deal on medicines regulation pharmatimes
January 30, 2018
The Brexit Health Alliance is again warning that medicines supply in the UK is in danger of being disrupted if the issue of co-operative regulation is not addressed during Brexit negotiations.
‘No-deal’ Brexit could cost NHS £500m a year pharmatimes
October 18, 2017
A ‘no-deal’ Brexit that ends healthcare arrangements between the UK and the EU could end up costing the NHS as much as £500 million a year
Brexit move creates EMA risk: report pharmatimes
September 29, 2017
The Brexit-inspired need to move the London HQ of the European Medicines Agency will throw up two major risks when it comes to patients and the approval of new medicines, according to a new report.
UK’s post-Brexit strategy looks to life sciences industry pharmafile
August 31, 2017
The UK Government had already announced, as part of its industrial plan, that the life sciences were regarded as a key part of British industry when looking towards a post-Brexit industrial future.
EMA reveals 'business continuity plan' for Brexit, cuts resources from non-essential areas pharmafile
August 03, 2017
The uncertainty caused by Brexit has been and continues to be far-reaching, and perhaps most impactful for business, organisations and their practices.
Patients at risk in Brexit negotiations, warns Alliance pharmatimes
August 02, 2017
The Brexit Health Alliance is warning that patients could be at risk if their interests are not protected in negotiations over the UK’s departure from the European Union.

Previous page 1 2 3 4 5 6 7 8 Next page